Literature DB >> 17602295

The organization and financing of end-stage renal disease in Spain.

José Luño1.   

Abstract

While the prevalence of end-stage renal disease (ESRD) in Spain is high, the incidence in comparison to the United States and Japan is low. Spain's rate of deceased organ donation is the highest in the world, and its renal transplant incidence rate is also relatively high. In addition, ESRD care represents a large portion of the overall health care budget. Quality of care in the National Health Service is not determined by competition or performance rewards; instead, several health agencies and scientific societies monitor it. Nevertheless, nephrologists with low salaries have relatively few professional and economic incentives to improve quality.

Entities:  

Mesh:

Year:  2007        PMID: 17602295     DOI: 10.1007/s10754-007-9021-z

Source DB:  PubMed          Journal:  Int J Health Care Finance Econ        ISSN: 1389-6563


  25 in total

1.  [Renal donation and transplantation in Spain 2002].

Authors:  M T Naya; G Garrido; N Cuende; J Cañón; B Miranda
Journal:  Nefrologia       Date:  2003 Sep-Oct       Impact factor: 2.033

2.  USRDS: the United States Renal Data System.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

3.  [Dialysis and Transplant Registry of the Spanish Society of Nephrology and regional registries. Rapport 2001].

Authors:  K López Revuelta; R Saracho; F García López; M A Gentil; P Castro; J Castilla; J A Gutiérrez; E Martín-Martínez; R Alonso; R Bernabéu; M A Munar; V Lorenzo; N Vega; R Escallada; T Sierra; M Lara; C Estébanez; M Clèries; E Vela; S Tallón; M J García-Blasco; O Zurriaga; C Vázquez; A Sánchez-Casajús; A Torralbo; R Rodado; A Genovés; J Ripoll; J L Asín; A Magaz; J Aranzábal
Journal:  Nefrologia       Date:  2004       Impact factor: 2.033

4.  Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries.

Authors:  P C van Dijk; K J Jager; F de Charro; F Collart; R Cornet; F W Dekker; C Grönhagen-Riska; R Kramar; T Leivestad; K Simpson; J D Briggs
Journal:  Nephrol Dial Transplant       Date:  2001-06       Impact factor: 5.992

5.  The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology.

Authors:  Ronald L Pisoni; Brenda W Gillespie; David M Dickinson; Kenneth Chen; Michael H Kutner; Robert A Wolfe
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

6.  Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999.

Authors:  Bénédicte Stengel; Solenne Billon; Paul C W Van Dijk; Kitty J Jager; Friedo W Dekker; Keith Simpson; J Douglas Briggs
Journal:  Nephrol Dial Transplant       Date:  2003-09       Impact factor: 5.992

7.  Factors that influence the development of an organ donation program.

Authors:  R Matesanz
Journal:  Transplant Proc       Date:  2004-04       Impact factor: 1.066

8.  Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Erwin Hecking; Jennifer L Bragg-Gresham; Hugh C Rayner; Ronald L Pisoni; Vittorio E Andreucci; Christian Combe; Roger Greenwood; Keith McCullough; Harold I Feldman; Eric W Young; Philip J Held; Friedrich K Port
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

9.  Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Ronald L Pisoni; Jennifer L Bragg-Gresham; Eric W Young; Tadao Akizawa; Yasushi Asano; Francesco Locatelli; Juergen Bommer; Jose Miguel Cruz; Peter G Kerr; David C Mendelssohn; Philip J Held; Friedrich K Port
Journal:  Am J Kidney Dis       Date:  2004-07       Impact factor: 8.860

10.  The organization and financing of kidney dialysis and transplant care in the United States of America.

Authors:  Richard A Hirth
Journal:  Int J Health Care Finance Econ       Date:  2007-12
View more
  8 in total

Review 1.  End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).

Authors:  Avi Dor; Mark V Pauly; Margaret A Eichleay; Philip J Held
Journal:  Int J Health Care Finance Econ       Date:  2007-09

2.  International Study of Health Care Organization and Financing of renal services in England and Wales.

Authors:  Tricia Nicholson; Paul Roderick
Journal:  Int J Health Care Finance Econ       Date:  2007-12

3.  International study of health care organization and financing: development of renal replacement therapy in Germany.

Authors:  Werner Kleophas; Helmut Reichel
Journal:  Int J Health Care Finance Econ       Date:  2007-09

4.  A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events.

Authors:  Anne-Line Couillerot-Peyrondet; Cléa Sambuc; Yoël Sainsaulieu; Cécile Couchoud; Isabelle Bongiovanni-Delarozière
Journal:  Eur J Health Econ       Date:  2016-05-05

5.  The financing and organization of medical care for patients with end-stage renal disease in Sweden.

Authors:  Björn Wikström; Michael Fored; Margaret A Eichleay; Stefan H Jacobson
Journal:  Int J Health Care Finance Econ       Date:  2007-12

Review 6.  International Study of Health Care Organization and Financing for end-stage renal disease in France.

Authors:  Isabelle Durand-Zaleski; Christian Combe; Philippe Lang
Journal:  Int J Health Care Finance Econ       Date:  2007-09

Review 7.  Belgium's mixed private/public health care system and its impact on the cost of end-stage renal disease.

Authors:  Wim Van Biesen; Norbert Lameire; Patrick Peeters; Raymond Vanholder
Journal:  Int J Health Care Finance Econ       Date:  2007-09

8.  Economic Burden of ESRD to the Malaysian Health Care System.

Authors:  Hirman Ismail; Mohd Rizal Abdul Manaf; Abdul Halim Abdul Gafor; Zaki Morad Mohamad Zaher; Adriana Irawati Nur Ibrahim
Journal:  Kidney Int Rep       Date:  2019-05-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.